๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study

โœ Scribed by Richard Herrmann; Marian Sturm; Kathryn Shaw; Duncan Purtill; Julian Cooney; Matthew Wright; Michael Phillips; Paul Cannell

Book ID
107619396
Publisher
Carden Jennings Publishing
Year
2011
Tongue
English
Weight
227 KB
Volume
95
Category
Article
ISSN
0925-5710

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Infliximab treatment for steroid-refract
Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: A case report
โœ Gaรซl Piton; Fabrice Larosa; Anne Minello; Marie-Claude Becker; Georges Mantion; ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 80 KB ๐Ÿ‘ 1 views

Acute graft-versus-host disease (GVHD) following orthotopic liver transplantation is a rare but severe disease with a 75% death rate in adults. Various therapeutic strategies have been proposed for steroid-refractory GVHD, but there is still no consensus. Tumor necrosis factor-alpha is a key inflamm

Intra-arterial methylprednisolone for th
Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease
โœ Laurie A. Milner; Michael W. Becker; Steven H. Bernstein; Lauren Bruckner; Jonat ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 681 KB

Staging System and chromosomal abnormalities determined by standard metaphase karyotype and/or fluorescence in situ hybridization (FISH). Treatment-induced adverse events were graded according to the National Cancer Institute common terminology criteria for adverse events (CTCAE) version 4.0. For r

In vivo CAMPATH-1 monoclonal antibodies:
In vivo CAMPATH-1 monoclonal antibodies: A novel mode of therapy for acute graft-versus-host disease
โœ Varadi, Gabor; Or, Reuven; Slavin, Shimon; Nagler, Arnon ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 205 KB ๐Ÿ‘ 2 views

CHOP, COP plui doxorubicin. ,'According to NCI criteria (Cheson el al. 151). (PD) was registered in one patient. Median time to disease progression for patients in PR or SD was 9 months (range, 1-14 months) (Table I). The results of the prehent study, although based on a small number of patients,